ICU Medical’s first quarter results in 2026 were marked by outperformance against Wall Street expectations, with revenue and non-GAAP earnings per share both coming in above consensus. Management attributed much of the quarter’s strength to robust growth in the Infusion Systems and consumables businesses, driven by improved installation execution and favorable product mix. CEO Vivek Jain highlighted that “the strongest growth driver was LVP by far and away in the segment,” referencing large volume pumps as a key contributor. Meanwhile, Vital Care revenues declined, partly due to the company’s ongoing efforts to exit non-core product lines and focus resources on its core infusion therapy offerings.

Is now the time to buy ICUI? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From ICU Medical’s Q1 Earnings Call

• Jayson Bedford (Raymond James) asked about the timing and significance of new hardware approvals. CEO Vivek Jain explained that FDA-required additional testing would delay launches, but emphasized the priority on Medfusion and continued confidence in the underlying technology.

• Brett Fishbin (KeyBanc Capital Markets) questioned the shift to more balanced Infusion Systems growth throughout the year. Jain attributed the change to better alignment of installation resources and improved scheduling with customer needs, reducing previous volatility.

• Joseph Conway (Needham) sought clarification on whether the resolution of the Smiths warning letter impacted customer behavior. Jain responded that he saw no direct correlation between regulatory developments and commercial activity, citing broad industry scrutiny.

• Jason Bednar (Piper Sandler) probed the impact of higher price points for new infusion pumps. Jain stated that the technology’s value justified pricing and that the focus remains on holding firm rather than discounting in competitive settings.

• Michael Toomey (Jefferies) asked if margin improvements were sustainable and if guidance was being reiterated. CFO Brian Bonnell confirmed that original EBITDA and EPS guidance remained unchanged, despite highlighting puts and takes from cost and tariff changes.

Catalysts in Upcoming Quarters

Going forward, the StockStory team will be tracking (1) the cadence and success of new product rollouts and 510(k) clearances, especially in Infusion Systems and consumables, (2) progress on reducing integration and restructuring expenses as major projects conclude, and (3) continued execution on the Vital Care portfolio optimization strategy. The sustainability of gross margin improvements and the company’s ability to offset external cost pressures will also be closely monitored.

ICU Medical currently trades at $122.08, in line with $123.07 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

The Best Stocks for High-Quality Investors

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.